Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Antiviral Res ; 177: 104777, 2020 05.
Artigo em Inglês | MEDLINE | ID: mdl-32217151

RESUMO

The Hepatitis B Virus (HBV) ribonuclease H (RNaseH) is a promising but unexploited drug target. Here, we synthesized and analyzed a library of 57 amide-containing α-hydroxytropolones (αHTs) as potential leads for HBV drug development. Fifty percent effective concentrations ranged from 0.31 to 54 µM, with selectivity indexes in cell culture of up to 80. Activity against the HBV RNaseH was confirmed in semi-quantitative enzymatic assays with recombinant HBV RNaseH. The compounds were overall poorly active against human ribonuclease H1, with 50% inhibitory concentrations of 5.1 to >1,000 µM. The αHTs had modest activity against growth of the fungal pathogen Cryptococcus neoformans, but had very limited activity against growth of the Gram - bacterium Escherichia coli and the Gram + bacterium Staphylococcus aureus, indicating substantial selectivity for HBV. A molecular model of the HBV RNaseH templated against the Ty3 RNaseH was generated. Docking the compounds to the RNaseH revealed the anticipated binding pose with the divalent cation coordinating motif on the compounds chelating the two Mn++ ions modeled into the active site. These studies reveal that that amide αHTs can be strong, specific HBV inhibitors that merit further assessment toward becoming anti-HBV drugs.


Assuntos
Amidas/farmacologia , Antivirais/farmacologia , Vírus da Hepatite B/efeitos dos fármacos , Tropolona/farmacologia , Replicação Viral/efeitos dos fármacos , Amidas/química , Antivirais/química , Linhagem Celular , Descoberta de Drogas , Hepatite B/tratamento farmacológico , Vírus da Hepatite B/fisiologia , Humanos , Modelos Moleculares , Tropolona/síntese química , Tropolona/química
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA